Kiora, Senju Pharmaceutical Partner on Treatment of Retinal Diseases in Asia

Kiora Pharmaceuticals (NASDAQ: KPRX) has granted Senju Pharmaceutical an exclusive option for the development and commercialization of KIO-301, a molecular photoswitch therapy for retinal diseases, in key Asian markets including Japan and China. The deal has a potential value of $110 million plus royalties, starting with an immediate $1.25 million option fee. If exercised, Kiora will receive an additional mid-single digit million upfront payment plus development, regulatory, and commercial milestones. This agreement complements Kiora's existing partnership with Théa Open Innovation for markets outside Asia, bringing the total potential value of strategic partnerships to over $400 million plus royalties. KIO-301 is currently in the ABACUS-2 Phase 2 clinical trial, targeting 36 patients with ultra-low vision or no light perception due to retinitis pigmentosa. The therapy aims to restore visual function by targeting surviving retinal ganglion cells.

https://www.stocktitan.net/news/KPRX/kiora-pharmaceuticals-and-senju-pharmaceutical-partner-on-kio-301-4cj0p81zt36n.html